Fig. 4. PFS and OS with durvalumab–ceralasertib and with durvalumab plus olaparib, danvatirsen or oleclumab in HUDSON in patient subgroups.
Figure shows medians and 80% CI per Kaplan–Meier methodology.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.